UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia

Am J Hematol. 2019 Nov;94(11):E283-E285. doi: 10.1002/ajh.25596. Epub 2019 Aug 9.

Authors

Alessandra Iurlo¹, Cristina Bucelli¹, Daniele Cattaneo¹, Giorgia Virginia Levati¹, Benedetta Viani¹, Dario Tavazzi², Dario Consonni³, Luca Baldini¹, Maria Domenica Cappellini²

Affiliations

¹ Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
² Department of Clinical Sciences and Community Health, University of Milan, and Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
³ Epidemiology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

PMID: 31364196
DOI: 10.1002/ajh.25596

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Drug Resistance, Neoplasm
Drug Substitution
Female
Fusion Proteins, bcr-abl / antagonists & inhibitors
Genetic Association Studies
Genotype
Gilbert Disease / complications*
Gilbert Disease / genetics
Glucuronosyltransferase / antagonists & inhibitors
Glucuronosyltransferase / genetics*
Hematologic Diseases / chemically induced
Humans
Hyperbilirubinemia / chemically induced*
Hyperbilirubinemia / genetics
Leukemia, Myeloid, Chronic-Phase / complications
Leukemia, Myeloid, Chronic-Phase / drug therapy*
Leukemia, Myeloid, Chronic-Phase / mortality
Male
Middle Aged
Neoplasm Proteins / antagonists & inhibitors
Progression-Free Survival
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / therapeutic use
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrimidines / adverse effects*
Pyrimidines / therapeutic use
TATA Box / genetics
Young Adult

Substances

Antineoplastic Agents
Neoplasm Proteins
Protein Kinase Inhibitors
Pyrimidines
UGT1A1 enzyme
Glucuronosyltransferase
Protein-Tyrosine Kinases
Fusion Proteins, bcr-abl
nilotinib